3.66

1.95% 0.07

After Hours: 3.62 -0.04 -1.09%

Cardiff Oncology Inc (CRDF)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Cardiff Oncology Inc stock is traded at $3.66, with a volume of 635.01K. It is up +1.95% in the last 24 hours and up +4.27% over the past month. Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Previous Close:

$3.59

Open:

$3.65

24h Volume:

635.01K

Relative Volume:

0.56

Market Cap:

$286.06M

Revenue:

$488.00K

Net Income/Loss:

$-41.44M

P/E Ratio:

-3.9355

EPS:

-0.93

Net Cash Flow:

$-31.47M

1W Performance:

+15.82%

1M Performance:

+4.27%

6M Performance:

-22.13%

1Y Performance:

+62.67%

1-Day Range:

$3.59

$3.69

1-Week Range:

$3.07

$3.70

52-Week Range:

$2.01

$5.6395

Cardiff Oncology Inc Stock (CRDF) Company Profile

Name

Cardiff Oncology Inc

Sector

Healthcare (1160)

Industry

Biotechnology (651)

Phone

858-952-7570

Address

11055 FLINTKOTE AVENUE, SAN DIEGO, CA

Employee

Twitter

@cardiffoncology

Next Earnings Date

2024-10-31

Latest SEC Filings

CRDF's Discussions on Twitter

Compare CRDF with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRDF Cardiff Oncology Inc	3.66	286.06M	488.00K	-41.44M	-31.47M	-0.93
VRTX Vertex Pharmaceuticals Inc	459.62	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	547.36	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	331.91	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	543.48	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	245.49	28.51B	3.81B	-644.79M	-669.77M	-6.24

Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-06-24	Initiated	Craig Hallum	Buy
Jan-05-22	Initiated	William Blair	Outperform
Dec-08-21	Initiated	Robert W. Baird	Outperform
Aug-09-21	Resumed	Maxim Group	Buy
Oct-22-20	Initiated	H.C. Wainwright	Buy
Oct-08-20	Initiated	Piper Sandler	Overweight

View All

Cardiff Oncology Inc Stock (CRDF) Latest News

Jun 18, 2025

Cardiff Oncology (CRDF) Stock Reacts to Delayed Clinical Data Up - GuruFocus

Jun 18, 2025

CRDF Set to Release Key Clinical Data Amid Leadership Changes | CRDF Stock News - GuruFocus

Jun 18, 2025

Cardiff Oncology (CRDF) Welcomes New Chief Medical Officer | CRD - GuruFocus

Jun 18, 2025

Jun 17, 2025

Cardiff Oncology (CRDF) Shares Drop 11% After Leadership Change - GuruFocus

Jun 17, 2025

Cardiff Oncology appoints Dr. Roger Sidhu as Chief Medical Officer - MarketScreener

Jun 17, 2025

Cardiff Oncology appoints Roger Sidhu as new Chief Medical Officer - Investing.com

Jun 17, 2025

Bank of America Corp DE Sells 11,352 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World

Jun 17, 2025

Jun 10, 2025

Two Sigma Investments LP Trims Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World

Jun 10, 2025

Jun 09, 2025

Two Sigma Advisers LP Trims Stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World

Jun 09, 2025

Jun 05, 2025

ProShare Advisors LLC Acquires New Shares in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World

Jun 05, 2025

Jun 04, 2025